FDA approves Icotyde, a new oral IL-23 therapy for plaque psoriasis
CURRENT BRIEF VERSION: Johnson & Johnson said the US Food and Drug Administration approved Icotyde, the brand name for icotrokinra, for moderate-to-severe plaque psoriasis in adults and in pediatric patients age 12 and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. The approval, announced March 18, 2026, gives the market a new oral IL-23 pathway therapy and, according to J&J, the first targeted oral peptide approved in this category. The company said the decision was supported by four Phase 3 ICONIC studies involving about 2,500 patients, including trials in adolescents, difficult-to-treat sites such as the scalp and genitals, and head-to-head studies against deucravacitinib. (investor.jnj.com)
Why it matters: While this is a human medicine approval, it’s relevant to veterinary professionals as a signal of where inflammatory disease drug development is heading: more oral, targeted immunology agents designed to match biologic-like efficacy with easier administration. That trend can shape pet parent expectations around chronic immune-mediated care, influence comparative discussions in translational medicine, and reinforce broader industry interest in cytokine-pathway targeting beyond injectables. The competitive picture is also moving quickly: independent coverage noted the commercial significance of an oral psoriasis drug meant to compete with established injectable biologics, and Takeda has also reported late-stage plaque psoriasis data for oral TYK2 inhibitor zasocitinib, with NDA plans starting in its fiscal 2026. (statnews.com) (pharmashots.com)
What to watch: Next will be launch uptake, payer access, and whether icotrokinra’s broader development program in psoriatic arthritis, ulcerative colitis, and Crohn’s disease advances on the timelines outlined by the companies. It will also be worth watching how Icotyde lands in an increasingly competitive oral psoriasis market as other late-stage agents, including zasocitinib, post strong Phase 3 results against placebo and apremilast. (irp.cdn-website.com) (pharmashots.com)